Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19)
Collections
Research team
Clin Trials & Stats Unit
Language
eng
Date accepted
2023-09-12
Citation
The Lancet Oncology,
Publisher
Elsevier